Literature DB >> 11592434

Is hyperhomocysteinemia due to the oxidative depletion of folate rather than to insufficient dietary intake?

D Fuchs1, M Jaeger, B Widner, B Wirleitner, E Artner-Dworzak, F Leblhuber.   

Abstract

Hyperhomocysteinemia is considered as a risk factor for cardiovascular diseases. Usually, an inverse relationship exists between homocysteine and folate levels, and supplementation with folate lowers homocysteine concentrations in patients. Therefore, hyperhomocysteinemia is mainly ascribed to the insufficient dietary intake of folate. Hyperhomocysteinemia has also been observed in infections and inflammatory diseases. Oxidative stress appears to be involved in the pathogenesis of these disorders, and associations have been found between homocysteine and e.g., neopterin concentration. Increased neopterin concentration indicates immune system activation and also allows an estimate of thus elicited oxidative stress. It may be relevant that the active cofactor, tetrahydrofolate, is very susceptible to oxidation. Immunologically induced oxidative stress could lead to folate depletion resulting in hyperhomocysteinemia. Thus, hyperhomocysteinemia in patients can be considered as an indirect consequence of hyperconsumption of antioxidant vitamins during prolonged states of immune activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592434     DOI: 10.1515/CCLM.2001.113

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  12 in total

Review 1.  Folate and Alzheimer: when time matters.

Authors:  Margareta Hinterberger; Peter Fischer
Journal:  J Neural Transm (Vienna)       Date:  2012-05-25       Impact factor: 3.575

2.  Oxidative balance and colon and rectal cancer: interaction of lifestyle factors and genes.

Authors:  Martha L Slattery; Abbie Lundgreen; Bill Welbourn; Roger K Wolff; Christopher Corcoran
Journal:  Mutat Res       Date:  2012-04-15       Impact factor: 2.433

3.  Insulin, glucose and glycated hemoglobin in Alzheimer's and vascular dementia with and without superimposed Type II diabetes mellitus condition.

Authors:  R O Domínguez; E R Marschoff; E M Guareschi; M G Repetto; A L Famulari; M A Pagano; J A Serra
Journal:  J Neural Transm (Vienna)       Date:  2007-08-30       Impact factor: 3.575

4.  Early increase of plasma homocysteine in sepsis patients with poor outcome.

Authors:  Martin Ploder; Katharina Kurz; Andreas Spittler; Gabriele Neurauter; Erich Roth; Dietmar Fuchs
Journal:  Mol Med       Date:  2010-03-26       Impact factor: 6.354

5.  Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells.

Authors:  K Schroecksnadel; B Frick; B Wirleitner; H Schennach; D Fuchs
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

6.  Cobalamin deficiency, hyperhomocysteinemia, and dementia.

Authors:  Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

7.  Pretreatment with vitamins E and C prevent the impairment of memory caused by homocysteine administration in rats.

Authors:  Eleonora A Reis; Alexandra I Zugno; Renata Franzon; Bárbara Tagliari; Cristiane Matté; Marcelo L Lammers; Carlos A Netto; Angela T S Wyse
Journal:  Metab Brain Dis       Date:  2002-09       Impact factor: 3.584

8.  Inhibition of Na(+),K(+)-ATPase activity in hippocampus of rats subjected to acute administration of homocysteine is prevented by vitamins E and C treatment.

Authors:  Angela T S Wyse; Alexandra I Zugno; Emilio L Streck; Cristiane Matté; Thiago Calcagnotto; Clovis M D Wannmacher; Moacir Wajner
Journal:  Neurochem Res       Date:  2002-12       Impact factor: 3.996

Review 9.  Antioxidants, inflammation and cardiovascular disease.

Authors:  Harald Mangge; Kathrin Becker; Dietmar Fuchs; Johanna M Gostner
Journal:  World J Cardiol       Date:  2014-06-26

10.  Homocysteine and cognitive impairment; a case series in a General Practice setting.

Authors:  Andrew McCaddon
Journal:  Nutr J       Date:  2006-02-15       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.